A phase III trial evaluating Keytruda (pembrolizumab) plus Lenvima (lenvatinib) in certain patients with advanced, metastatic or recurrent endometrial cancer following one prior platinum-based regimen in any setting met its dual primary endpoints of progression-free survival and overall survival.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe